New York, Jan 15, 2026, 19:32 EST — After-hours
- TMO gained $2.85, or 0.46%, and held steady in after-hours trading
- Investors are eager for the results and outlook set for Jan. 29
- Recent headlines highlight a leadership reshuffle and a new Nvidia lab-automation partnership
Shares of Thermo Fisher Scientific Inc (TMO) climbed $2.85, or 0.46%, to close at $624.65 on Thursday, holding steady in after-hours trading. The stock had touched $629.75 earlier, flirting with its session peak.
The lab tools and pharma-services supplier will release its Q4 and full-year 2025 results before markets open on Jan. 29. A conference call is scheduled for 8:30 a.m. ET. Investors hope for clear signals on demand in labs and biopharma after a turbulent period for the sector.
The move unfolded against a stronger backdrop. The S&P 500 advanced 0.26%, and the Dow Jones Industrial Average picked up 0.60% on Thursday. Meanwhile, Danaher gained 0.82%, and Becton Dickinson edged up 0.45%, according to MarketWatch data.
Thermo Fisher jumped 2.43% the day before, closing at $621.83, even as the broader market slipped. That left the stock roughly 1% shy of its 52-week peak of $628.08 hit on Jan. 6, per MarketWatch. Volume picked up, surpassing the stock’s 50-day average.
On Jan. 14, Thermo Fisher rolled out a new Invitrogen TaqMan Cells-to-CT HepatoExpress kit designed to accelerate gene expression analysis in liver cells, a key step in early drug discovery. “There is a need to incorporate” metabolism studies earlier to screen more compounds, said Parita Ghia, senior director and general manager at the company. PharmiWeb.com
Thermo Fisher is ramping up its focus on automation and software. On Jan. 12, the company announced a strategic partnership with Nvidia to develop AI-driven lab solutions and automation tools. Their goal: link instruments and lab data directly to AI software. “Artificial intelligence coupled with laboratory automation will transform how scientific work is performed,” said Thermo Fisher exec Gianluca Pettiti. Nvidia’s Kimberly Powell described it as “lab-in-the-loop” science. Thermo Fisher Scientific Investors
Speaking at the J.P. Morgan Healthcare Conference, CEO Marc Casper highlighted Thermo’s pharma services unit has landed contracts to assist clients shifting production back to the U.S. from Europe or Asia — known in the industry as reshoring. “There’s a very big focus on reshoring more production and activity to the U.S.,” Casper noted. Thermo pointed to last year’s acquisition of Sanofi’s Ridgefield, New Jersey manufacturing site as part of this strategy. Reuters
A regulatory filing revealed upcoming management changes. According to an SEC filing, COO Michel Lagarde will exit on March 31, and executive vice president Frederick Lowery is set to leave on Feb. 28. Starting March 1, Casper will take over as chairman and CEO, while Pettiti steps into the role of president and chief operating officer. (An 8-K is the form companies use to report significant corporate events.)
The timing remains a key risk. It can take years for contract manufacturing changes to translate into consistent revenue, and new automation upgrades don’t guarantee immediate boosts in orders or profits. Should biotech funding tighten up again or pharma clients delay project launches, the recent rally toward the stock’s highs could lose steam.
Thermo Fisher will report earnings and lay out its 2026 outlook on Jan. 29. Investors are also watching March 1 closely for a key leadership change, with additional executive shifts expected later that month.
